Nationwide Fund Advisors’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Nationwide Fund Advisors’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,227	Closed	-$7.24K	–	3310
2017 Q1	$11K	Hold	3,227	–	–	﹤0.01%	3123
2016 Q4	$17K	Hold	3,227	–	–	﹤0.01%	3094
2016 Q3	$81K	Hold	3,227	–	–	﹤0.01%	2957
2016 Q2	$80K	Hold	3,227	–	–	﹤0.01%	2996
2016 Q1	$93K	Hold	3,227	–	–	﹤0.01%	2854
2015 Q4	$120K	Buy	3,227 +102	+3%	+$4.5K	﹤0.01%	2777
2015 Q3	$152K	Buy	3,125 +230	+8%	+$16.1K	﹤0.01%	2710
2015 Q2	$200K	Buy	+2,895	New	+$134K	﹤0.01%	2714

Other funds holding ANTH

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Nationwide Fund Advisors's ANTH Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2017, closing a stake of 3,227 shares — an estimated $7.24K sold.

Nationwide Fund Advisors first reported a position in ANTH in Q2 2015 and held it in 8 quarters. The position peaked at $200K in Q2 2015. 40 funds tracked by Wall St. Rank hold ANTH as of Q2 2017.

Nationwide Fund Advisors reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 3,227 Anthera Pharmaceuticals, Inc. shares in Q2 2017, an estimated $7.24K.
Nationwide Fund Advisors first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2015 and held it in 8 quarters.
Nationwide Fund Advisors's Anthera Pharmaceuticals, Inc. position peaked at $200K in Q2 2015.
40 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.